Biotricity's Founder & CEO Waqaas Al-Siddiq to Present at World Heart Summit May 19-21 in Geneva, Switzerland

Dr. Waqaas will address, meet with, world leaders and medical innovators on pressing challenges and solutions in global cardiovascular health, digital health and AI

REDWOOD CITY, CA / ACCESSWIRE / May 10, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced that its Founder & CEO Waqaas Al-Siddiq will be speaking at the World Heart Summit 2023 taking place in Geneva, Switzerland on May 19-21.

Dr. Al-Siddiq will participate in a panel discussion entitled "Capitalizing on the Digital Transformation for Heart Health." The panel will highlight the significance of digital innovation and AI, in response to the increasing global rise of heart disease, the shortage of cardiac practitioners, and how technology innovators can aim to deliver more comprehensive and effective care to more people and patients.

The World Heart Summit brings together an eclectic global community of leaders and visionaries from different sectors, driven by their shared commitment to alleviate the impact of cardiovascular disease (CVD) worldwide. Attendees will engage in transformational conversations, learn from and exchange ideas with other leaders in the field.

"This Summit offers tremendous opportunity to expand our horizons globally with a terrific venue to showcase our line of cardiac monitors, solutions and cloud-based Biosphere ecosystem, seamlessly integrated throughout the world, by connecting with physicians, cardiologists, investors, consumers, and patients alike," said Dr. Al-Siddiq.

"Biotricity is at the forefront of transforming cardiac care by deploying state-of-the-art solutions ranging from wellness cardiac monitors for consumers, to sophisticated remote real-time cardiac devices connected to sensitive diagnostic software for cardiologists and their CVD diagnosed patients," Dr. Al-Siddiq added. "In their totality, our solutions are documented to improve outcomes and take costs out of the health care system while boosting cardiologists' efficiency."

About World Health Summit 2023

The 8th edition of the World Heart Summit will take place in Geneva, Switzerland - the heart of global health diplomacy - on the 19th -21st of May 2023, ahead of the 76th World Health Assembly.

Leaders and innovators from government, business, civil society and academia will engage in transformational conversations as we explore some of the most pressing challenges in global cardiovascular health.

For more info, please visit:
https://world-heart-federation.org/world-heart-summit-2023/

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the nine months ended December 31, 2022, the Company incurred a net loss attributable to common stockholders of $14.7 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

CONTACTS

Media relations
STiR-communications
Greg Salsburg
greg@STiR-communications.com

Investor relations
Biotricity Investor Relations
Investors@biotricity.com

SOURCE: Biotricity, Inc.